As a third-generation platinum antineoplastic drug, lobaplatin (LBP) can effectively induce apoptosis, repress proliferation and enhance radiosensitivity by inhibiting the PI3K/AKT pathway in ESCC 92. Here, AKT1 is linked to esophageal squamous cell carcinoma.